VIP and migraine disorder: In a randomized clinical trial, a monoclonal antibody targeting the PAC1 receptor (AMG 301) failed in migraine prevention.52 The data in the current study on VIP-induced migraine provide alternatives to the role of PAC1 receptor in migraine induction.